Epigenetics in heart failure phenotypes

被引:33
作者
Berezin, Alexander [1 ]
机构
[1] State Med Univ Zaporozhye, Dept Internal Med, 26 Mayakovsky Av, UA-69035 Zaporozhe, Ukraine
来源
BBA CLINICAL | 2016年 / 6卷
关键词
Heart failure with reduced ejection fraction; Heart failure with preserved ejection fraction; Epigenetic modifications; Chromatin remodeling;
D O I
10.1016/j.bbacli.2016.05.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic heart failure (HF) is a leading clinical and public problemposing a higher risk of morbidity and mortality in different populations. HF appears to be in both phenotypic forms: HF with reduced left ventricular ejection fraction (HFrEF) and HF with preserved left ventricular ejection fraction (HFpEF). Although both HF phenotypes can be distinguished through clinical features, co-morbidity status, prediction score, and treatment, the clinical outcomes in patients with HFrEF and HFpEF are similar. In this context, investigation of various molecular and cellular mechanisms leading to the development and progression of both HF phenotypes is very important. There is emerging evidence that epigenetic regulation may have a clue in the pathogenesis of HF. This review represents current available evidence regarding the implication of epigenetic modifications in the development of different HF phenotypes and perspectives of epigenetic-based therapies of HF. (C) 2016 The Author. Published by Elsevier B.V.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 108 条
[1]   microRNAs: Tiny regulators with great potential [J].
Ambros, V .
CELL, 2001, 107 (07) :823-826
[2]  
Aune SE, 2015, FRONT NEUROL, V6, DOI [10.3389/fneur.2015.00145, 10.3389/fneur.2.015.00-145]
[3]   Global MicroRNA Profiling of the Mouse Ventricles during Development of Severe Hypertrophic Cardiomyopathy and Heart Failure [J].
Bagnall, Richard D. ;
Tsoutsman, Tatiana ;
Shephard, Rhian E. ;
Ritchie, William ;
Semsarian, Christopher .
PLOS ONE, 2012, 7 (09)
[4]  
Berezin A., 2016, TRANSL MED SUNNYVALE, V6, P176, DOI DOI 10.4172/2161-1025.1000176
[5]  
Berezin A., 2016, J DATA MIN GENOMICS, V7, P195, DOI DOI 10.4172/2153-0602.1000195
[6]  
Berezin A., 2016, BIOMARK J, V2, P14
[7]  
Berezin A.E., 2015, J CLIN TRIAL CARDIOL, V2, P1
[8]  
Berezin A.E., 2015, ANGIOLOGY, V3, P4, DOI [DOI 10.4172/2329-9495.1000161, 10.4172/2329-9495.1000161]
[9]  
Berezin A. E., 2015, J DIS MARKERS, V2, P1035
[10]  
Berezin A.E., 2015, J CARDIOL THER, V2, P273